This site is intended for healthcare professionals only

Issue:

Early View

GLP-1 receptor agonists have a wide range of benefits

Cardiovascular – December 2019 digest

Meta-analysis of GLP-1 receptor agonist cardiovascular outcomes trials finds improved cardiovascular, mortality and kidney outcomes 

Kristensen SL, Rørth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol  7: 776–85

  • GLP-1 receptor agonists have been shown to reduce HbA1c as well as modestly improving lipid levels, body weight and blood pressure in people with type 2 diabetes. 
  • Investigators performed a systematic review and meta-analysis of large randomised controlled cardiovascular outcomes trials to establish the effects of GLP-1 receptor agonists on cardiovascular, kidney and safety outcomes in patients with type 2 diabetes.
  • Seven trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND and PIONEER 6) including over 56,000 participants were included in the meta-analysis. The trials studied six different GLP-1 receptor agonists.
  • There was a significant 12% reduction in major adverse cardiovascular events associated with the use of GLP-1 receptor agonists. Breaking this down into separate cardiovascular outcomes, a 9% drop in fatal and non-fatal myocardial infarction, 16% reduction in fatal and non-fatal stroke, and 12% fewer deaths from cardiovascular causes occurred with GLP-1 receptor agonist treatment. This class of drugs had a similar effect on cardiovascular outcomes in all patient subgroups analysed.
  • GLP-1 receptor agonists significantly reduced all-cause mortality, hospital admission for heart failure and renal outcomes.
  • The investigators concluded that GLP-1 receptor agonists improved cardiovascular and renal outcomes and reduced the risk of mortality in people with type 2 diabetes.

Click here to access the article in full

Related content
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.